Itacitinib

Drug Profile

Itacitinib

Alternative Names: INCB-039110; INCB-039110-adipate; INCB39110

Latest Information Update: 15 May 2017

Price : $50

At a glance

  • Originator Incyte Corporation
  • Developer AstraZeneca; Incyte Corporation
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Graft-versus-host disease; Hodgkin's disease; Non-small cell lung cancer
  • Phase I/II Non-Hodgkin's lymphoma; Solid tumours
  • Discontinued Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 15 May 2017 Incyte Corporation plans the phase III GRAVITAS-301 trial for Graft versus host disease (Combination therapy, Treatment-naive) (PO)
  • 11 May 2017 Incyte Corporation plans a phase II trial for Myelofibrosis (Combination therapy, Monotherapy) in USA (NCT03144687)
  • 08 May 2017 Incyte corporation terminates a phase II trial in Hodgkin's disease (Combination therapy, Second-line therapy or greater, Recurrent) in USA (PO) (NCT02456675) due to the changing treatment landscape for the development of new agents in combination in Hodgkin lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top